Saniona reports data from exploratory Phase IIa of Tesomet for Prader-Willi

Saniona AB (SSE:SANION) said data from an exploratory Phase IIa trial evaluating once-daily Tesomet tesofensine/metoprolol in patients with Prader-Willi syndrome showed that plasma concentrations of tesofensine were two to four times higher compared to previous studies in obese and diabetic patients